Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2014-03-11 (12 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-ETIENNE-DE-MONTLUC (44360), Loire-Atlantique
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE THIERCELIN : revenue, balance sheet and financial ratios
SELARL PHARMACIE THIERCELIN is a French company
founded 12 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-ETIENNE-DE-MONTLUC (44360),
this company of category PME
shows in 2023 a revenue of 2.6 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE THIERCELIN (SIREN 800958225)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
2 639 339 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
153 518 €
80 488 €
176 721 €
295 517 €
185 477 €
186 508 €
180 793 €
135 874 €
167 530 €
EBITDA
N/C
N/C
217 783 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
6.7%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE THIERCELIN generates positive net income of 154 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 168 k€ -> 154 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
153 518 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 23%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 72%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
23.341%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
71.628%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
295.803
201.575
136.365
87.527
69.196
50.759
37.498
34.257
23.341
Financial autonomy
23.697
31.012
39.976
50.398
53.593
58.552
64.768
67.035
71.628
Repayment capacity
None
None
None
None
None
None
2.467
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
6.866%
None%
None%
Sector positioning
Debt ratio
23.342025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good
In 2025, the debt ratio of SELARL PHARMACIE THIERCELIN (23.34) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
71.63%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of SELARL PHARMACIE THIERCELIN (71.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
2.47 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of SELARL PHARMACIE THIERCELIN (2.47) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 280.52. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
392.557
399.462
519.465
501.05
332.907
323.771
275.448
296.803
280.517
Interest coverage
None
None
None
None
None
None
1.748
None
None
Sector positioning
Liquidity ratio
280.522025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of SELARL PHARMACIE THIERCELIN (280.52) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
1.75x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELARL PHARMACIE THIERCELIN (1.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE THIERCELIN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
172 507 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
18
0
0
Customer payment term (days)
0
0
0
0
0
0
4
0
0
Supplier payment term (days)
0
0
0
0
0
0
23
0
0
Positioning of SELARL PHARMACIE THIERCELIN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE THIERCELIN is estimated at
2 438 651 €
(range 1 654 880€ - 3 826 580€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1654k€2438k€3826k€
2 438 651 €Range: 1 654 880€ - 3 826 580€
NAF 5 année 2025
Valuation method used
Net Income Multiple
153 518 €
×
15.9x
=2 438 652 €
Range: 1 654 881€ - 3 826 580€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE THIERCELIN with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE THIERCELIN
What is the revenue of SELARL PHARMACIE THIERCELIN ?
The revenue of SELARL PHARMACIE THIERCELIN in 2023 is 2.6 M€.
Is SELARL PHARMACIE THIERCELIN profitable?
Yes, SELARL PHARMACIE THIERCELIN generated a net profit of 154 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE THIERCELIN ?
The headquarters of SELARL PHARMACIE THIERCELIN is located in SAINT-ETIENNE-DE-MONTLUC (44360), in the department Loire-Atlantique.
Where to find the tax return of SELARL PHARMACIE THIERCELIN ?
The tax return of SELARL PHARMACIE THIERCELIN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE THIERCELIN operate?
SELARL PHARMACIE THIERCELIN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart